The Procter & Gamble Company (PG) vs Colgate-Palmolive Company (CL)
PG leads on valuation, momentum and balance sheet; CL leads on profitability and earnings momentum
The two household-products makers are priced almost the same on forward P/E (24.05× for PG, 24.42× for CL), but they differ on trailing measures, where PG's P/E is 25.79× against 38.77× for CL. Qanvo's scorecard favours PG on valuation (67 vs 33), technical momentum (80 vs 20), financial resilience (60 vs 40) and lower risk (75 vs 25). CL leads on profitability and quality (67 vs 33) and earnings momentum (67 vs 33), and growth is mixed at 50 each, so there is no clear leader. CL's trailing figures are distorted by a December 2025 quarterly loss and by thin equity of 288.0M, which limits some comparisons. PG has stronger recent price returns, while CL has stronger 1-year and longer returns (26.4% vs 17.8% over 1 year).
Business overview
Both companies sit in Consumer Staples, in the Household & Personal Products industry, and both are US-listed on the NYSE. The main difference is scale and mix. Procter & Gamble has a market cap of $413.36B against $79.59B for Colgate-Palmolive, roughly five times larger. P&G describes five segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. Colgate reports two divisions: Oral, Personal and Home Care, and Pet Nutrition. The revenue splits differ. In fiscal 2026, P&G's largest segment was Fabric & Home Care at $30.31B (34.83% of sales), and Non-US sales were 52.07% of the total. Colgate's fiscal 2025 revenue was 77.37% Oral, Personal and Home Care ($15.77B) and 22.63% Pet Nutrition ($4.61B). Colgate's geographic breakdown is not provided in the facts, so footprints cannot be compared directly. P&G has 104,000 employees versus 33,600 at Colgate. The two overlap in oral care and home care, but P&G is broader and Colgate has a pet nutrition arm.
- P&G's market cap of $413.36B is roughly five times Colgate's $79.59B.
- P&G reports five segments, while Colgate reports two, with Pet Nutrition at 22.63% of its fiscal 2025 revenue.
- P&G's Non-US revenue share is 52.07%; Colgate's geographic split is not in the facts.
- P&G has 104,000 employees against 33,600 at Colgate.
Valuation
On forward P/E (based on analyst estimates) the two are almost level: 24.05× for P&G and 24.42× for Colgate. The gap opens on trailing measures. Trailing P/E is 25.79× for P&G against 38.77× for Colgate, PEG is 3.91× against 5.14×, and price/sales is 4.70× against 3.74×. On EV/EBITDA, P&G is 17.85× and Colgate 22.22×. Colgate offers the higher free-cash-flow yield, 4.76% against 3.71%. Qanvo's valuation scorecard favours P&G (67 vs 33), driven by the trailing P/E, PEG and EV/EBITDA. Against its own 5-year range, P&G's trailing P/E of 25.79× sits almost exactly at its median of 25.81× (range 20.92× to 30.91×). Colgate's 38.77× is above its median of 31.97× and nearer the top of its 21.58× to 43.95× range. Versus sector peers, both rank high: P&G's forward P/E is at the 81st percentile (sector median 16.61×) and Colgate's at the 83rd. Colgate's trailing P/E is inflated by lower reported EPS, while its forward multiple is much lower, so its premium reflects depressed earnings as well as price. Colgate also has the stronger profitability scores, which may partly explain a premium; P&G has the lower risk score.
- Trailing P/E is 25.79× for P&G against 38.77× for Colgate, though forward P/E is close at 24.05× against 24.42×.
- P&G trades at its 5-year median trailing P/E of 25.81×, while Colgate is above its own median of 31.97×.
- Colgate has the higher free-cash-flow yield, 4.76% against 3.71%.
- Both sit at the 81st and 83rd percentiles of sector forward P/E, well above the 16.61× median.
Growth
Reported revenue growth favours Colgate. Its latest annual growth is 5.91% against 3.52% for P&G, and its 3-year compound rate is 4.29% against 2.00%. Latest-quarter revenue growth is 3.98% for P&G and 4.64% for Colgate. Colgate has grown revenue for six straight quarters, from $4.94B in the December 2024 quarter to $5.37B in September 2026. P&G's quarters are more seasonal, ranging from $19.78B to $23.28B, and its annual revenue rose from $76.12B in fiscal 2021 to $87.03B in fiscal 2026. EPS tells a different story. Year-over-year EPS growth is -3.07% for P&G and -28.46% for Colgate, the latter reflecting a quarter with a net loss of $37.0M (EPS -0.046) in December 2025. Over three years, EPS compounds at 3.91% for P&G and 7.28% for Colgate. Colgate's quarterly EPS has recovered to $0.94. Analyst estimates, which are opinions rather than results, point to next-year EPS growth of 6.15% for P&G and 4.75% for Colgate. Consensus EPS for the current fiscal year is $6.98 for P&G and $3.92 for Colgate. Qanvo's growth scorecard is mixed, at 50 each, so there is no clear leader.
- Colgate's latest annual revenue growth is 5.91% against 3.52% for P&G.
- The 3-year EPS compound rate is 7.28% for Colgate against 3.91% for P&G, but last-year EPS growth is -28.46% against -3.07%.
- Analysts estimate next-year EPS growth of 6.15% for P&G and 4.75% for Colgate.
- Colgate has six consecutive quarters of revenue growth, while P&G's streak is one.
Profitability, cash flow & financial health
Qanvo's scorecard gives CL the lead on profitability and quality (67 versus 33 for PG, relative ranks within this pair). CL has the higher gross margin at 60.61% versus 49.78%, and a much higher ROIC at 53.31% versus 19.92%. PG leads on operating margin (22.55% versus 20.54%) and net margin (18.23% versus 9.65%). Free cash flow margins are close at 17.80% for CL and 17.45% for PG. CL's ROE of 358.92% is not meaningful as a comparison, because its total equity is only 288.0M. PG's ROE is 29.58%. Over the past year, PG's gross margin fell 1.20% and its operating margin fell 1.60%. CL's gross margin rose 0.46% while its operating margin fell 1.07%. CL's trailing EPS growth of -28.46% reflects a weak Q4 FY2025, when net income was -37.0M. On financial health, PG leads the scorecard on resilience (60 versus 40). Its net debt/EBITDA is 0.96× versus 1.60× for CL, and its debt/equity is 0.71× versus 26.79×. PG's current ratio is 0.72× against 0.96× for CL. Interest coverage is 21.96× for PG and 17.48× for CL.
- CL's gross margin of 60.61% is above PG's 49.78%, while PG's net margin of 18.23% is nearly double CL's 9.65%.
- CL's ROIC of 53.31% is well above PG's 19.92%, but CL's 358.92% ROE reflects thin equity of 288.0M and is not a clean comparison.
- PG's net debt/EBITDA of 0.96× is below CL's 1.60%, and its debt/equity of 0.71× compares with 26.79× for CL.
- PG's free cash flow of 15.34B on a 17.45% margin compares with 3.79B on 17.80% for CL, so cash conversion is similar relative to sales.
Shareholder returns & capital allocation
Both are long-time dividend payers with 29 years of dividend growth in the data. PG's dividend yield is 2.52% versus 2.12% for CL, and PG's quarterly dividend is 1.09 per share, against 0.53 for CL. PG's payout ratio is 65.09%, below CL's 82.62%, which leaves PG more room relative to earnings. Three-year dividend growth is 4.99% for PG and 3.46% for CL. Both companies are shrinking their share counts. PG's shares changed by -1.21% over the past year and CL's by -1.38%, so CL's reduction is slightly larger. In PG's latest fiscal year, dividends paid were 10.23B and buybacks were 5.03B, against free cash flow of 15.15B. That is roughly the full amount of free cash flow, with dividends taking the larger part. CL's latest fiscal year shows dividends paid of 1.82B and buybacks of 1.21B, against free cash flow of 3.63B, so the combined payout was also close to the full free cash flow figure. PG's buybacks have declined from 11.01B in fiscal 2021. CL's have stayed around 1.1B to 1.7B.
- PG's dividend yield of 2.52% is above CL's 2.12%, with a lower payout ratio of 65.09% versus 82.62%.
- PG's three-year dividend growth of 4.99% is above CL's 3.46%, and both show 29 years of growth.
- CL's share count fell 1.38% over a year versus 1.21% for PG, a small difference.
- PG's fiscal 2026 dividends of 10.23B and buybacks of 5.03B compare with CL's fiscal 2025 dividends of 1.82B and buybacks of 1.21B.
Earnings intelligence
Both companies have beaten EPS estimates in each of the last four reported quarters, but CL's record is steadier. CL's EPS surprises were 4.75% (Oct 30, 2026), 4.54%, 2.86% and 4.17%, and it has an EPS beat streak of 18. PG's were 6.38% (Oct 22, 2026), 1.42%, 1.92% and 1.08%, with a streak of 7. PG's latest beat was the larger, and its revenue surprise of 2.11% compares with 0.61% for CL. PG's revenue surprises in the prior three quarters were -0.83%, 3.43% and -0.40%, against 0.06%, 2.07% and 2.09% for CL. Stock reactions differed. PG moved 2.67% after the latest report, then -3.30%, 1.85% and 2.80%. CL moved 4.58%, -1.88%, 0.01% and 7.80%. Qanvo's earnings momentum scorecard names CL the leader (67 vs 33), helped by its 1.48% 30-day EPS revision against 0.06% for PG. Both next reports are estimated, not confirmed: PG on Jan 21, 2027 and CL on Jan 29, 2027. No company guidance appears in the facts. The latest report arguably helped CL's relative case more, given the steadier beats and upward estimate revisions.
- CL's EPS beat streak is 18 quarters against 7 for PG.
- PG's latest EPS surprise of 6.38% exceeds CL's 4.75%.
- CL's 30-day EPS revision is 1.48% versus 0.06% for PG.
- Next reports are unconfirmed: PG Jan 21, 2027 and CL Jan 29, 2027.
Technicals, relative performance & risk
PG leads over short horizons by price return: 8.9% vs 6.7% over 1 month, 20.0% vs 10.4% over 3 months and 20.6% vs 10.8% over 6 months. CL leads over longer ones: 26.4% vs 17.8% over 1 year, 32.0% vs 14.3% over 3 years and 28.4% vs 16.7% over 5 years. With dividends reinvested, the 1-year figures are 28.7% for CL and 20.4% for PG, and the 5-year figures are 43.8% and 31.9%. Both trade above their 20-, 50- and 200-day averages. PG is 4.21%, 10.56% and 14.42% above them; CL is 3.25%, 8.95% and 10.18% above. PG's RSI of 68.49 sits nearer overbought territory than CL's 62.49, and PG's relative strength rating is 90 against 88. PG is 1.08% below its 52-week high and CL is 2.16% below. On risk, PG's 30-day volatility is 25.26% against 27.44% for CL, and its 1-year drawdown is -16.15% against -17.48%. Beta is -0.05 for PG and -0.1 for CL. Qanvo's momentum and lower-risk scorecards both favour PG. The technical strength sits alongside forward P/Es of 24.05 for PG and 24.42 for CL, and CL's trailing P/E of 38.77 is well above PG's 25.79, so price strength is not matched by cheap valuations.
- PG's 3-month price return of 20.0% is roughly double CL's 10.4%.
- CL's 1-year price return of 26.4% beats PG's 17.8%.
- PG's RSI of 68.49 is above CL's 62.49.
- PG's 30-day volatility of 25.26% is below CL's 27.44%.
Analyst & ownership sentiment
Analyst opinion is split in label but close in substance. PG's consensus label is Buy with a rating score of 2.4, while CL's is Hold on the 29/23/1 and 19/25/2 buy/hold/sell counts in the detailed consensus (PG 29 Buy, 23 Hold, 1 Sell; CL 19 Buy, 25 Hold, 2 Sell). CL's separate rating score is 2.29, so the two labels do not line up neatly. These are analysts' opinions, not forecasts of outcomes. Mean price targets are estimates: PG $171.87 against a $171.72 share price (0.09% upside), CL $103.17 against $99.61 (3.57% upside). PG had one downgrade in the last 30 days (Bank of America Securities, to Underperform) and CL had none. CL's 30-day EPS revision is 1.48%, versus 0.06% for PG. Institutions hold 84.25% of CL and 69.25% of PG, though 13F filings lag by weeks (data as of Jun 30, 2026). Insiders were net sellers in both: PG had 27 sells in 90 days (-36.8M net) and CL 6 (-8.0M), with no buys at either. Short interest is 2.32% of float for CL against 0.93% for PG.
- PG's mean target implies 0.09% upside versus 3.57% for CL, both analyst estimates.
- CL's 30-day EPS revision of 1.48% is above PG's 0.06%.
- CL's short interest of 2.32% of float is above PG's 0.93%.
- PG insiders had 27 sells in 90 days versus 6 for CL, with no buys at either.
Risks & catalysts
Valuation is the shared risk. Forward P/E is 24.05× for PG and 24.42× for CL, both well above the industry median of 17.09×. CL's trailing P/E of 38.77× compares with PG's 25.79×, and CL's trailing earnings are depressed by a loss in Q4 FY2025, so that multiple is distorted. Both depend on analysts' EPS estimates (FY1 consensus 6.98 for PG, 3.92 for CL) holding. Balance sheet and margins differ. CL's net debt/EBITDA is 1.60× against 0.96× for PG, and its equity is only 288.0M, which is why its debt/equity of 26.79× and ROE of 358.92% are not comparable with PG's 0.71× and 29.58%. PG's operating margin fell 1.60% over a year and CL's 1.07%. CL's pet nutrition is 22.63% of revenue, a concentration PG does not share, while PG's largest segment, Fabric & Home Care, is 34.83%. Price risk: both trade near 52-week highs after strong 3-month runs, and CL's 30-day implied volatility is 24.81% versus PG's 21.56%. Catalysts: PG's next earnings are Jan 21, 2027 and CL's Jan 29, 2027, neither confirmed. Past earnings moves averaged 2.40% for PG and 2.87% for CL over eight quarters.
- Forward P/E of 24.05× for PG and 24.42× for CL are both above the 17.09× industry median.
- CL's net debt/EBITDA of 1.60× is above PG's 0.96×.
- CL's 30-day implied volatility is 24.81% against 21.56% for PG.
- Next earnings are Jan 21, 2027 for PG and Jan 29, 2027 for CL, both unconfirmed.
Analysis written November 18, 2026. AI-generated, for information only; not investment advice.